✕
Login
Register
EN
Translate page
EN
English
ES
Español
FR
Français
DE
Deutsch
ZH
中文
AR
العربية
PT
Português
RU
Русский
JA
日本語
KO
한국어
HI
हिन्दी
IT
Italiano
Back to News
Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata
Benzinga Newsdesk
www.benzinga.com
Neutral 87.0%
Neg 0%
Neu 87%
Pos 0%
-SEC Filing
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment